Difference between revisions of "Dutasteride (Avodart)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
Line 1: Line 1:
 
==General information==
 
==General information==
Class/mechanism: 5 alpha-reductase, inhibits conversion of testosterone to dihydrotestosterone (DHT).  Competitively inhibits type 1 and 2 5 alpha-reductase isoenzymes by forming a stable enzyme complex with them.<ref name="insert">[http://us.gsk.com/products/assets/us_avodart.pdf Dutasteride (Avodart) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/SHORTER MEDICATION NAME.pdf Dutasteride (Avodart) package insert (locally hosted backup)]</ref>
+
Class/mechanism: 5 alpha-reductase, inhibits conversion of testosterone to dihydrotestosterone (DHT).  Competitively inhibits type 1 and 2 5 alpha-reductase isoenzymes by forming a stable enzyme complex with them.<ref name="insert">[http://us.gsk.com/products/assets/us_avodart.pdf Dutasteride (Avodart) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/dutasteride.pdf Dutasteride (Avodart) package insert (locally hosted backup)]</ref>
 
<br>Route: PO
 
<br>Route: PO
 
<br>Extravasation: n/a
 
<br>Extravasation: n/a
Line 7: Line 7:
  
 
==Patient drug information==
 
==Patient drug information==
*[http://www.uptodate.com/contents/SHORTER MEDICATION NAME-patient-drug-information Dutasteride (Avodart) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/SHORTER MEDICATION NAME-patient-drug-information Dutasteride (Avodart) patient drug information (UpToDate)]</ref>
+
*[http://www.uptodate.com/contents/dutasteride-patient-drug-information Dutasteride (Avodart) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/dutasteride-patient-drug-information Dutasteride (Avodart) patient drug information (UpToDate)]</ref>
  
 
==References==
 
==References==
 
<references/>
 
<references/>

Revision as of 18:08, 10 January 2012

General information

Class/mechanism: 5 alpha-reductase, inhibits conversion of testosterone to dihydrotestosterone (DHT). Competitively inhibits type 1 and 2 5 alpha-reductase isoenzymes by forming a stable enzyme complex with them.[1][2]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].

Patient drug information

References